Recent advance in antiviral drugs for hepatitis C

Journal of Central South University (Medical Sciences)

Volumn 36, Issue 11, 2011, Pages 1025-1036

  Liu, Jia ^a   Shi, Shuang ^a   Zhuang, Hui ^a   Luo, Guangxiang ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antiviral drug; Combination therapy; Hepatitis c virus (hcv); Ns3 protease inhibitor; Ns5a inhibitor; Ns5b polymerase inhibitor

Indexed keywords

EID: 84555190280     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-7347.2011.11.001     Document Type: Article

References (100)

1. Lavanchy D. The global burden of hepatitis C[J]. Liver Int, 2009, 29(Suppl) : 74-81.
2. Alter M J, Kruszon-Moran D, Nainan O V, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994[J]. N Engl J Med, 1999, 341(8): 556-562. (Pubitemid 29384163)
3. Alter M J, Margolis H S, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team[J]. N Engl J Med, 1992, 327(27): 1899-1905. (Pubitemid 23006964)
4. Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alfada plus ribavirin for chronic hepatitis C virus infection [J]. N Engl J Med, 2002, 347(13): 975-982.
5. Manns M P, McHutchison J G, Gordon S C, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a random-ised trial[J]. Lancet, 2001, 358(9286): 958-965. (Pubitemid 32913521)
6. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J]. Nat Genet, 2009, 41(10): 1105-1109.
7. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J]. Nat Genet, 2009, 41(10): 1100-1104.
8. McCarthy J J, Li J H, Thompson A, et al. Replicated association between an 1128 B gene variant and a sustained response to pegylated interferon and ribavirin[J]. Gastroenterology, 2010, 138(7): 2307-2314.
9. Branch A D, Stump D D, Gutierrez J A, et al. The hepatitis C virus alternate reading frame (ARF) and its family of novel products; the alternate reading frame protein/F-protein, the double-frameshift protein, and others [J]. Semin Liver Dis, 2005, 25(1): 105-117. (Pubitemid 40322355)
10. Xu Z, Choi J, Yen T S, et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift [ J ]. Embo J, 2001, 20 (14): 3840-3848. (Pubitemid 32691795)
11. Cun W, Jiang J, Luo G. The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus [J]. J Virol, 2010, 84(21): 11532-11541.
12. Jiang J,Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles [J]. J Virol, 2009, 83(24): 12680-12691.
13. Chang K S, Jiang J, Cai Z, et al. Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture[J]. J Virol, 2007, 81(24): 13783-13793. (Pubitemid 350247871)
14. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81[J]. Science, 1998, 282(5390): 938-941. (Pubitemid 28507525)
15. Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus[J]. Embo J, 2002, 21(19): 5017-5025.
16. Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein reeeptor[J]. Proc Natl Acad Sci USA, 1999, 96(22) : 1276612771.
17. Evans M J, von Hahn T, Tscheme D M, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry [J]. Nature, 2007, 446(7137): 801-805. (Pubitemid 46582027)
18. Ploss A, Evans M J, Gaysinskaya V A, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse CeIIs[J]. Nature, 2009, 457(7231): 882-886.
19. Patargias G, Zitzmann N, Dwek R, et al. Protein-protein interactions : modeling the hepatitis C virus ion channel p7 [J]. J Med Chem, 2006, 49(2): 648-655. (Pubitemid 43157494)
20. Griffin S D, Beales L P, Clarke D S, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine[J]. FEBS Lett, 2003, 535(1-3): 34-38. (Pubitemid 36126351)
21. ] Clarke D, Griffin S, Beales L, et al. Evidence for the formation of a heptameric on channel complex by the hepatitis C virus p7 protein in vitro[J]. J Biol Chem, 2006, 281 (48): 37057-37068. (Pubitemid 46042176)
22. Pavlovic D, Neville D C, Argaud O, et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives[J]. Proc Natl Acad Sci USA, 2003, 100(10): 6104-6108. (Pubitemid 36576938)
23. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence [J]. Adv Virus Res, 2004, 63: 71-180. (Pubitemid 39752303)
24. Blight K J, Kolykhalov A A, Rice C M. Efficient initiation of HCV RNA replication in cell culture[J]. Science, 2000, 290 (5498): 1972-1974.
25. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line [J]. Science, 1999, 285(5424): 110-113. (Pubitemid 29307577)
26. El-Hage N, Luo G. Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA[J]. J Gen Virol, 2003, 84(Pt 10): 2761-2769. (Pubitemid 37220255)
27. Evans M J, Rice C M, Goff S P. Phosphorylation of hepatitis C virus nonstructural protein 5 A modulates its protein interactions and viral RNA replication[J]. Proc Natl Acad Sci USA, 2004, 101(35): 13038-13043. (Pubitemid 39167579)
28. Moradpour D, Gosert R, Egger D, et al. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex[J]. Antiviral Res, 2003, 60(2): 103-109. (Pubitemid 37452453)
29. Wang C, Gale M Jr, Keller B C, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication[J]. Mol Cell, 2005, 18(4):425434.
30. Tellinghuisen T L, Foss K L, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein [J]. PLoS Pathog, 2008, 4(3): 000032.
31. ] Behrens S E, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus[J]. Embo J, 1996, 15(1): 12-22. (Pubitemid 26020384)
32. Luo G, Hamatake R K, Mathis D M, et al. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus[J]. J Virol, 2000, 74(2): 851-863. (Pubitemid 30036222)
33. Love R A, Parge H E, Wickersham J A, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsinlike fold and a structural zinc binding site[J]. Cell, 1996, 87 (2): 331-342. (Pubitemid 26359010)
34. Kim J L, Morgenstern K A, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide[J]. Cell, 1996, 87(2) : 343-355. (Pubitemid 26359011)
35. Yan Y, Li Y, Munshi S, et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus; a 2.2 A resolution structure in a hexagonal crystal form[J]. Protein Sci, 1998, 7 (4): 837-847.
36. Kim J L, Morgenstern K A, Griffith J P, et al. Hepatitis C virus NS3 RNA helioase domain with a bound oligonucleotide; the crystal structure provides insights into the mode of unwinding[J]. Structure, 1998, 6(1): 89-100. (Pubitemid 28084402)
37. Kang L W, Cho H S, Cha S S, et al. Crystallization and preliminary X-ray crystallographic analysis of the helioase domain of hepatitis C virus NS3 protein [J]. Acta Crystallogr D Biol Crystallogr, 1998, 54(Pt 1): 121-123.
38. Lesburg C A, Cable M B, Ferrari E, et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site[J]. Nat Struct Biol, 1999, 6 (10): 937-943. (Pubitemid 29463307)
39. Bressanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus[J]. Proc Natl Acad Sci USA, 1999, 96(23): 13034-13039.
40. Melnikova I. Hepatitis C therapies[J]. Nature Reviews Drug Discovery, 2008, 7 (10): 799-800.
41. Reesink H W, Zeuzem S, Weegink C J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950 : a phase Ib, placebo-controlled, randomized study [J]. Gastroenterology, 2006, 131(4): 997-1002. (Pubitemid 44498690)
42. Sarrazin C, Kieffer T L, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir[J]. Gastroenterology, 2007, 132(5): 1767-1777. (Pubitemid 46677938)
43. Forestier N, Reesink H W, Weegink C J, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C[J]. Hepatology, 2007, 46(3): 640-648. (Pubitemid 47436108)
44. Lawitz E, Rodriguez-Torres M, Muir A J, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients[J]. J Hepatol, 2008, 49(2): 163-169.
45. Bumey T, Dusheiko G. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients[J]. Expert Rev Ami Infect Ther, 2011, 9(2) : 151-160.
46. McHutchison J G, Everson G T, Gordon S C, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection[J]. N Engl J Med, 2009, 360(18): 1827-1838.
47. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection [J]. N Engl J Med, 2009, 360(18): 1839-1850.
48. McHutchison J G, Manns M P, Muir A J, et al. Telaprevir for previously treated chronic HCV infection [J]. N Engl J Med, 2010, 362(14); 1292-1303.
49. Jacobson I M, McHutchison J G, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection [J]. N Engl J Med, 2011, 364(25): 2405-2416.
50. Sherman K E, Flamm S L, Afdhal N H, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response; final results of phase 3 ILLUMINATE study[J]. Hepatology, 2010, 52(Suppl 1): 401A- 402A.
51. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection[J]. N Engl J Med, 2011, 364(25): 2417-2428.
52. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders [ J ]. Gastroenterology, 2007, 132(4): 1270-1278. (Pubitemid 46627577)
53. Schiff E, Poordad F, Jacobson I, et al. Boceprevir (B) combination therapy in null responders (NR) : response dependent on interferon responsiveness[J]. J Hepatol, 2008, 48(Suppl 2) : S46.
54. Kwo P Y, Lawitz E J, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRlNT-1) : an open-label, randomised, multicentre phase2 trial[J]. Lancet, 2010, 376(9742): 705-716.
55. Poordad F, McCone J Jr, Bacon B R, et al. Boceprevir for untreated chronic HCV genotype 1 infection[J]. N Engl J Med, 2011, 364(13): 1195-1206.
56. Bacon B R, Gordon S C, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection [J]. N Engl J Med, 2011, 364(13): 1207-1217.
57. Gao M, Nettles R E, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effcet[J]. Nature, 2010, 465(7294): 96-100.
58. Lee C, Ma H, Hang J Q, et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein [J]. Virology, 2011, 414 (1): 10-18.
59. Fridell R A, Qiu D, Valera L, et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052[J]. J Virol, 2011, 85 (14); 7312-7320.
60. Nettles R, Chien C, Chung E, et al. BMS-790052 is a first-inclass potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection : results from a proof-of-concepl study[J]. Hepatology, 2008, 48(Suppl 1):1025A.
61. Nettles R, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1[J]. Hepatology, 2011, [ Epub ahead of print].
62. Fridell R A, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system[J]. Antimicrob Agents Chemother, 2010, 54 (9): 3641-3650.
63. Fridell R A, Wang C, Sun J H, et al. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052; In Vitro and In Vivo correlations [J]. Hepatology,2011, [Epub ahead of print].
64. Pol S, Everson G, Ghalib R, et al. Once-daily NS5A inhibitor (BMS-790052) plus peginterferon-alpha-2a and ribavirin pro-duces high rates of extended rapid virologie response in treatment-naive HCV-genotype 1 subjects:phase 2a trial[J]. J Hepatol, 2010, 52(Suppl 1): S462.
65. Pol S, Ghalib R H, Rustgi V K, et al. First report of SVR12 for a NS5A replication complex inhibitor, BMS-790052 in combination with peg-lFNα-2a and RBV: phase 2a trial in treatment-naive HCV-genotype-1 subjects[J]. J Hepatol, 2011, 54 (Suppl 1): S544-S545.
66. Lok A, Gardiner D, Lawitz E, et al. Combination therapy with BMS-790052 and BMS-650032 alone or with peglFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders [J]. Hepatology, 2010, 52 (Suppl 1): 877A.
67. Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders [J]. J Hepatol, 2011, 54(Suppl 1): S536.
68. ] Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy [J]. Hepatology, 2007, 46(Suppl 1): 862A.
69. Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg BID for 28 days [J]. J Hepatol 2008, 48 (Suppl 2): S29.
70. Thompson A J, McHutchison J G. Review article; investigational agents for chronic hepatitis C [J]. Aliment Pharmacol Ther, 2009, 29(7); 689-705.
71. Gane E, Rodriguez-Torres M, Nelson D, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders; results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days [J]. Hepatology, 2008, 48 (Suppl 1): 1024A.
72. Jensen D M, Wedemeyer H, Herring R W, et al. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PEGIFN alfa-2a (40KD)/RVB: planned week 12 interim analysis from the propel study [J]. Hepatology, 2010, 52(Suppl 1): 360A.
73. Cane E, Roberts S, Stedman C, et al. Early on-treatment responses during pegylated IFN plus ribavirin are increased following 13 days of combination nucleoside polymerase (RG7128) and protease (RG7227) inhibitor therapy (INFORM-I) [J]. J Hepatol, 2010, 52(Suppl 1): S291-S292.
74. Shih IH, Vliegen I, Peng B, et al. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5 B polymerase [J]. Antimicrob Agents Chemother, 2011, 55(9) : 41964203.
75. Bavisotto L, Wang C C, Jacobson IM, et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects [J]. Hepatology, 2007, 46 (Suppl 1): 255A.
76. Harris J, Bae A, Sun SC, et al. Antiviral response and resistance analysis of treatment-naive HCV infected subjects receiving single and multiple doses of GS-9190[J]. Hepatology, 2010, 52(Suppl 1); 772A.
77. Lawitz E, Jacobson I, Godofsky E, et al. A phase2b trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)/ PEG/RBV to 48 weeks treatment with PEG/RBV for chronic genotype 1 HCV infection [ J ]. J Hepatol, 2011, 54 (Suppl 1): S181.
78. Shi S T, Herlihy K J, Graham J P, et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase [J]. Antimicrob Agents Chemother, 2009, 53(6) : 2544-2552.
79. Hammond J L, Purohit V S, Fang J, et al. Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor PF00868554 following multiple dose administration in healthy volunteers [J]. Hepatology, 2008, 48 (Supple 1): 1159A-1160 A.
80. Hammond J L, Rosario M C, Wagner F, et al. Antiviral activity of the HCV polymerase inhibitor PF-00868554 administered as monotherapy in HCV genotype 1 infected subjects[J]. Hepatology, 2008, 48(Suppl 1) : 1024A-1025A.
81. Jacobson I, Pockros P, Lalezari J, et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1 [J]. J Hepatol, 2009, 50(Suppl 1); S382-S383.
82. Jacobson I, Pockros P, Lalezari J, et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2a and ribavirin in chronically-infected HCV genotype-1 patients[J]. J Hepatol, 2010, 52(Suppl 1): S465.
83. Mori J, Hammond J L, Srinivasan S, et al. Genotypic characterisation of filibuvir (PF-00868554) resistance in patients receiving four weeks co-administration of filibuvir with peg IFN/ RBV[J]. Hepatology, 2010, 52(Suppl 1): 722A-723A.
84. Dvory-Sobol H, Pang P S, Glenn J S. The future of HCV therapy: NS4B as an antiviral target [J]. Viruses, 2010, 2(11): 2481-2492.
85. Einav S, Gerber D, Bryson PD, et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis[ J]. Nat Biotechnol, 2008, 26(9): 1019-1027.
86. Einav S, Sobol H D, Gehrig E, et al. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors [J]. J Infect Dis, 2010, 202(1); 65-74.
87. Thompson A J, Patel K. Antisense inhibitors, ribozymes, and SiRNAs [J]. Clin Liver Dis, 2009, 13(3): 375-390.
88. Sakai A, Claire M S, Faulk K, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences [J]. Proc Natl Acad Sci USA, 2003, 100(20): 11646-11651. (Pubitemid 37205990)
89. Steinmann E, Penin F, Kallis S, et al. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions [J]. PLoS Pathog, 2007, 3(7); e103.
90. Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins [J]. Gastroenterology, 2005, 129 (3): 1031-1041. (Pubitemid 41242693)
91. Vermehren J.Sarrazin C. New HCV therapies on the horizon [J]. Clin Microbiol Infect, 2011, 17(2); 122-134.
92. Lupberger J, Zeisel M B, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy [J]. Nat Med, 2011, 17(5) : 589-595.
93. Clark V, Nelson D R. Novel interferons for treatment of hepatitis C virus[J]. Clin Liver Dis, 2009, 13(3): 351-363.
94. Leav B A, Sloan S, Blair B M. Safety and pharmacokinetics of a novel human monoclonal antibody directed against the E2 glycoprotein of hepatitis C virus (MBL-HCV1) in healthy volunteers[J]. J Hepatol, 2010, 52(Suppl 1): S118.
95. Rossignol J F, Eifert A, El-Gohary Y, et al. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin [J]. Gastroenterology, 136 (3): 856-862.
96. Bacon B R, Shiffman M L, Lim J K. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 naive patients: week 12 sustained virologie response rate [J]. J Hepatol, 52(Suppl 1): S463.
97. Shiffman M L, Ahmed A, Jacobson I M. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic hepatitis C genotype 1; final report [J]. J Hepatol, 2010, 52(Suppl 1): S461.
98. Muir A, Ghalib R, Lawitz E. A phase 1, multi-center, randomized, placebo-controlled, dose-escalation study of IMO2125, a TLR9 agonist, in hepatitis C-nonresponders [J]. J Hepatol, 2010, 52(Suppl 1): S14.
99. Janssen H L, Bruijne J, Bergmann J F. ANA773, an oral inducer of endogenous interferons that acts via TLR7, reduced serum viral load in patients chronically infected with HCV [J]. Hepatology, 2009, 50 (Suppl 4): 1022A.
100. Burke K P, Cox A L. Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence [J]. Immunol Res, 2010, 47(1-3): 216-227.